Boston Scientific Stops Roll-Out Of Lotus Edge TAVR To Resolve Locking Problem

The company is pulling the new version of its transcatheter aortic valve off of shelves in Europe after it received some reports that the device could not be fully locked, which prevents the procedure from being completed. In each of the reported cases, the patients could be treated with a different valve.

Boston Scientific Corp. announced it is voluntarily removing field inventory of the Lotus Edge repositionable transcatheter aortic valve system, just weeks after launching it at select few European sites, after receiving reports that some of the devices could not be locked after deployment.

If the valve cannot be locked once it is in place in the aortic annulus, the procedure cannot be completed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By 

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By 

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By 

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

More from Medtech Insight

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By 

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

European MedTech Keeps Calm Despite US Threats Of 30% Tariffs

 

MedTech Europe wants the EU to continue its commitment to reach a negotiated tariff solution with the US and measured restraint amid escalating trade tensions.

Medtech Will Benefit From Boost To EU’s Quantum Technology Initiative

 

The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”